Intravitreal Aflibercept (Eylea) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum

Trial Profile

Intravitreal Aflibercept (Eylea) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Choroidal neovascularisation
  • Focus Therapeutic Use
  • Acronyms EyNep
  • Most Recent Events

    • 18 Sep 2016 Planned End Date changed from 1 Aug 2017 to 1 Feb 2018.
    • 18 Sep 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Feb 2018.
    • 11 May 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top